PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Mirikizumab - Ulcerative colitis - moderately to severely active

PAD Profile : Mirikizumab - Ulcerative colitis - moderately to severely active

Keywords :
Ulcerative colitis, IBD, UC, NICE, intravenous Infusion, subcutaneous injection, anti-interleukin-23, anti-IL-23
Brand Names Include :
Omvoh

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
Comments :
No comments returned.

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
06 December 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves mirikizumab as a treatment option in line with the recommendations made in NICE TA925, for treating moderately to severely active ulcerative colitis.

Mirikizumab for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More